MicroPort CardioFlow Medtech Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jeffrey R Lindstrom

Algemeen directeur

CN¥4.0m

Totale compensatie

Percentage CEO-salaris	59.8%
Dienstverband CEO	1.2yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	4yrs
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Jeffrey R Lindstrom's beloning veranderd ten opzichte van MicroPort CardioFlow Medtech's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CN¥349m
Mar 31 2024	n/a	n/a	-CN¥410m
Dec 31 2023	CN¥4m	CN¥2m	-CN¥472m

Compensatie versus markt: De totale vergoeding ($USD 562.75K ) Jeffrey R } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 816.84K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Jeffrey R te vergelijken met de prestaties van het bedrijf.

CEO

Jeffrey R Lindstrom (57 yo)

1.2yrs

Tenure

CN¥4,004,000

Compensatie

Mr. Jeffrey R Lindstrom is President, Executive Director & General Manager of MicroPort CardioFlow Medtech Corporation from August 29, 2023. He served as senior director of engineering in Edwards Lifescien...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jeffrey R Lindstrom	President	1.2yrs	CN¥4.00m	geen gegevens
Liang Zhao	Executive Director & First VP of Total Solutions	2.4yrs	CN¥3.91m	0.058% € 123.6k
Luying Yan	VP & Executive Director	4.1yrs	CN¥2.70m	0.042% € 88.8k
Xiangmei Li	Joint Company Secretary	4yrs	geen gegevens	geen gegevens
Lok Yee Chan	Joint Company Secretary	4yrs	geen gegevens	geen gegevens

4.0yrs

Gemiddelde duur

43yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 72X wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jeffrey R Lindstrom	President	1.2yrs	CN¥4.00m	geen gegevens
Liang Zhao	Executive Director & First VP of Total Solutions	2.4yrs	CN¥3.91m	0.058% € 123.6k
Luying Yan	VP & Executive Director	4.1yrs	CN¥2.70m	0.042% € 88.8k
Jonathan H. Chou	Independent Non-Executive Director	3.8yrs	CN¥254.00k	geen gegevens
Xia Wu	Non-Executive Director	5.2yrs	geen gegevens	geen gegevens
Guoming Chen	Non-Executive Chairman of the Board	4.1yrs	CN¥3.16m	0.031% € 65.1k
Junjie Zhang	Non-Executive Director	5.2yrs	geen gegevens	geen gegevens
Zhixiang Sun	Independent Non-Executive Director	3.8yrs	CN¥254.00k	geen gegevens
Jiandong Ding	Independent Non-Executive Director	3.2yrs	CN¥254.00k	0.0012% € 2.6k

3.8yrs

Gemiddelde duur

47yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 72X wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

MicroPort CardioFlow Medtech Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024

MicroPort Cardioflow Medtech Corporation Announces Executive Changes

Less than half of directors are independent

Less than half of directors are independent

MicroPort CardioFlow Medtech Announces Appointment of Zhao Liang as Executive Director

MicroPort CardioFlow Medtech Corporation Announces Resignation of Wu Guojia as an Executive Director

Recent updates

Now 22% undervalued after recent price drop

Now 28% undervalued

First half 2024 earnings released: CN¥0.024 loss per share (vs CN¥0.076 loss in 1H 2023)

Now 56% undervalued after recent price drop

MicroPort CardioFlow Medtech Corporation to Report First Half, 2024 Results on Aug 28, 2024

Now 48% undervalued after recent price drop

Full year 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.19 loss in FY 2022)

Forecast to breakeven in 2026

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.19 loss in FY 2022)

MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2023 Results on Mar 27, 2024

Microport Cardioflow Medtech Corporation Receives NMPA Approval for Registration Application of Anchorman LAAC System

MicroPort CardioFlow Medtech Corporation Completes Clinical Implantation Cases in Europe

MicroPort CardioFlow Medtech Corporation Announces First Two Clinical Applications of Third-Generation TAVI Product

First half 2023 earnings released: CN¥0.076 loss per share (vs CN¥0.052 loss in 1H 2022)

MicroPort Cardioflow Medtech Corporation Announces Executive Changes

MicroPort CardioFlow Medtech Corporation to Report First Half, 2023 Results on Aug 29, 2023

New major risk - Share price stability

New minor risk - Share price stability

Less than half of directors are independent

Full year 2022 earnings released: CN¥0.19 loss per share (vs CN¥0.079 loss in FY 2021)

Less than half of directors are independent

Microport Cardioflow Medtech Corporation Announces Registration in Colombia for Alwide Plus Balloon Catheter

First half 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.031 loss in 1H 2021)

MicroPort CardioFlow Medtech Corporation to Report Q2, 2022 Results on Aug 29, 2022

MicroPort CardioFlow Medtech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Microport Cardioflow Medtech Corporation Announces That the Transcatheter Mitral Valve Replacement System Independently Developed by the Group Was Successfully Applied by the Heart Team of Zhongshan Hospital

MicroPort CardioFlow Medtech Announces Appointment of Zhao Liang as Executive Director

Full year 2021 earnings released: CN¥0.079 loss per share (vs CN¥0.23 loss in FY 2020)

MicroPort CardioFlow Medtech Corporation Announces Resignation of Wu Guojia as an Executive Director

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.08 loss per share (vs CN¥0.23 loss in FY 2020)

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 22, 2022

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 22, 2022

Microport Cardioflow Medtech Corporation Successfully Registered Vitaflow Liberty Transcatheter Aortic Valve Implantation System in Argentina

Microport Cardioflow Medtech Corporation Announces Ce Mark Registration Application for Vitaflow Libertytm

No longer forecast to breakeven

Forecast to breakeven in 2023

Independent Non-Executive Director Hualiang Jiang has left the company

MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2020 Results on Mar 30, 2021

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd